Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

EGFR-Mutant NSCLC Treatment Paradigm on Verge of Disruption

August 18th 2017

Monotherapy with a tyrosine kinase inhibitor is the frontline standard of care for patients with advanced EGFR-mutant non–small cell lung cancer, with 3 currently approved agents: erlotinib, gefitinib, and afatinib.

The Future of Treatment in Follicular Lymphoma

August 15th 2017

Novel Therapies in FL: Benefits and Challenges

August 15th 2017

Combination Therapy's Role in Follicular Lymphoma

August 15th 2017

Impact of Copanlisib in Follicular Lymphoma

August 15th 2017

Considering the Value of PI3 Kinase Inhibitors in FL

August 15th 2017

Addressing Unmet Needs in Salvage Therapy for FL

August 15th 2017

The Evolving Landscape of Salvage Therapy for FL

August 15th 2017

Choosing Therapy for Relapsed/Refractory FL

August 15th 2017

Continuing FL Treatment: Maintenance and Surveillance

August 15th 2017

Systemic Treatment for Newly Diagnosed FL

August 15th 2017

Triggers to Initiate Therapy for Follicular Lymphoma

August 15th 2017

Risk Stratifying Patients With Follicular Lymphoma

August 15th 2017

Follicular Lymphoma: Diagnosis and Staging

August 15th 2017

Precision Medicine Moves Forward, 1 Validated Biomarker at a Time

August 15th 2017

This commentary from Maurie Markman, MD, highlights a critical required component for the development of effective novel antineoplastic strategies through the process widely known as precision cancer medicine.

Key Points for Treatment of Advanced HNSCC

August 10th 2017

Next Steps in Research for Immunotherapy for HNSCC

August 10th 2017

Immunotherapy in the Peri-Operative Setting of HNSCC

August 10th 2017

Immunotherapy Combinations for HNSCC

August 10th 2017

Emerging Checkpoint Inhibitors for HNSCC

August 10th 2017